Volume 13, Number 8 (Nov/Dec 2022)

JADPRO Live 2022: Reaching the Peak of Practice

The 2022 JADPRO Live conference was held in person from October 20 to 23 in Aurora, Colorado. I was excited to finally see peers I had only met virtually throughout these past 2 years. Numerous advanced practitioner–designed sessions on ...

Inclusion of Racial and Ethnic Minorities in Cancer Clinical Trials: 30 Years After the NIH Revitalization Act, Where Are We?

The lack of diversity in cancer trials is a multifaceted, decades-old problem that has remained persistent despite efforts to increase the number of participants from underrepresented racial and ethnic backgrounds. This lack of meaningfu...

Advanced Practitioner-Led Shared Visits: A Novel Approach to Cancer Survivorship

Background: The continued increase in the number of cancer survivors is encouraging and credited to better prevention, screening, and treatment. Cancer care authorities call for survivorship follow-up focusing on surveillance, health beh...

Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study

Background and Purpose: Clinical guidelines suggest that prophylactic antiepileptic drugs (AEDs) should be given to newly diagnosed seizure-naive brain tumor patients for up to 1 week after craniotomy. Yet, data suggest that prophylactic...

Liquid Biopsy for Guiding Treatment Decisions in Advanced Non–Small Cell Lung Cancer

Lung cancer is the leading cause of cancer-related deaths in the United States. The 5-year survival rates are poor with traditional therapy alone. New scientific advances in technology involving the human genome, including diagnostic too...

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

Background: Pegfilgrastim is recommended to be administered at least 24 hours following the completion of chemotherapy, yet some clinicians use a same-day administration protocol. In this meta-analysis, we compared the incidence of chemo...

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy

KRAS mutations are the most common alteration in human cancers, accounting for approximately 30% of mutations in multiple cancer types, including colorectal, pancreatic, non–small lung cancer, and ovarian. Of these, the KRAS p.G12C mutat...

Supporting Advanced Practice Fellowship During COVID-19

With the aging population and increasing number of cancer survivors contributing to a projected provider shortage, one solution is the specialization of nurse practitioners and physician assistants (part of the advanced practice provider...

What Is Happening to This Patient With a Rare Leukemia?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare cancer with primary sites in the skin and bone marrow and secondary sites in the lymph nodes, spleen, and central nervous system. First described in the 1990s, these cells ex...

Thank You to Our Peer Reviewers!